The mammarenavirus lymphocytic choriomeningitis virus (LCMV) is a globally distributed zoonotic pathogen that can be lethal in immunocompromised patients and can cause severe birth defects if acquired during pregnancy. The envelope glycoproteins of LCMV (LCMV GP) are initially expressed as a precursor polypeptide, GP-C, which is posttranslationally processed by a cellular protease into GP-1 and GP-2. GP-1 interacts with the cellular receptor for LCMV, which has been identified as alpha-dystroglycan. GP-2 contains the fusion peptide and the transmembrane domain.